DNA topoisomerases from pathogenic fungi: targets for the discovery of antifungal drugs
Open Access
- 1 December 1992
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 36 (12) , 2778-2784
- https://doi.org/10.1128/aac.36.12.2778
Abstract
DNA topoisomerases, a class of enzymes that change the topological structure of DNA, have been shown to be the target of many therapeutic agents, including antibacterial agents (quinolones) and anticancer agents. These drugs inhibit the enzyme in a unique way so that the enzyme is converted into a cellular poison. Candida albicans and Aspergillus niger are two major opportunistic fungal pathogens. Our results show that these fungi have high levels of both type I and type II topoisomerases (with a minimum of 5 x 10(5) ATP-independent relaxation units and 2 x 10(5) P-4 unknotting units per liter of wild-type C. albicans). The ATP-dependent type II topoisomerase (termed C. albicans topoisomerase II) was purified by approximately 2,000-fold from C. albicans cells by using a simple isolation scheme that consists of three column procedures: hydroxylapatite, phosphocellulose, and heparin-agarose chromatographies. The responses of the Candida and the calf thymus topoisomerase II to some known topoisomerase II inhibitors were measured. Etoposide and 4'-(9-acridinylamino)methanesulfon-m-anisidide, compounds known to inhibit catalysis and to enhance DNA breakage by mammalian topoisomerase II, and A-80198, an etoposide derivative, enhanced cleavage by both enzymes at similar concentrations of these compounds, with the response of the calf thymus topoisomerase II from slightly to fourfold higher in magnitude than the response of the Candida enzyme in the same concentration range. In contrast, A-75272 (a cytotoxic tricyclic quinolone) shows a slightly stronger DNA cleavage enhancement effect with the Candida enzyme than with the mammalian counterpart. The abundance of the enzyme in cells and the different drug responses of the host enzyme and the fungal enzyme suggest that the fungal topoisomerase may serve as a target for the discovery of effective and safe antifungal agents.Keywords
This publication has 42 references indexed in Scilit:
- Topoisomerase II: A potential target for novel antifungal agentsBiochemical and Biophysical Research Communications, 1989
- DNA supercoiling and prokaryotic transcriptionCell, 1989
- Simultaneous Purification of DNA Topoisomerase I and II from Eukaryotic CellsPreparative Biochemistry, 1989
- TOPOISOMERASES IN HUMAN DISEASEThe Lancet, 1988
- Mode of Action, and In Vitro and In Vivo Activities of the FluoroquinolonesThe Journal of Clinical Pharmacology, 1988
- Topoisomerase II: A specific marker for cell proliferation.The Journal of cell biology, 1986
- DNA TOPOISOMERASESAnnual Review of Biochemistry, 1985
- DNA TopoisomerasesAnnual Review of Biochemistry, 1981
- A Sign Inversion Mechanism for Enzymatic Supercoiling of DNAScience, 1979
- Interaction between DNA and an Escherichia coli protein ωJournal of Molecular Biology, 1971